Salvage radiation is radiotherapy given after radical prostatectomy when PSA becomes detectable or rises, or when pathology shows a high risk of microscopic cancer remaining. The aim is to eradicate disease in the prostate bed, with pelvic lymph nodes included in selected patients. Modern evidence generally supports early salvage radiotherapy rather than automatically giving radiation to every high-risk patient immediately after surgery, provided PSA is monitored closely. Treatment is most effective when started at a low PSA before visible metastatic disease develops, although the exact threshold and use of androgen-deprivation therapy depend on recurrence risk.

Why PSA should be very low after prostatectomy

After the whole prostate is removed, PSA should fall to an undetectable or very low level. A persistent or subsequently rising PSA suggests residual or recurrent prostate cancer, although confirmation and assay context matter.

Adjuvant versus early salvage radiation

Adjuvant radiotherapy is delivered before PSA recurrence because pathology is high risk. Early salvage radiotherapy is triggered by a detectable/rising PSA. Randomised evidence supports surveillance with early salvage for many men, reducing unnecessary radiation while preserving cancer control.

Role of PSMA PET

PSMA PET can identify nodal or distant recurrence and alter radiation fields or systemic treatment. However, a negative scan at a low PSA does not prove there is no microscopic prostate-bed disease and should not automatically delay potentially curative salvage radiotherapy.

When ADT is added

Short- or longer-term androgen deprivation may improve outcomes in selected patients with higher-risk features such as higher PSA at salvage, Grade Group, rapid PSA doubling time, seminal-vesicle involvement or nodal risk. The benefit must be balanced against metabolic, sexual and bone side effects.

Side effects

Urinary frequency/urgency, bowel irritation and fatigue can occur during treatment. Late effects include rectal bleeding, urinary stricture, incontinence worsening and erectile dysfunction. Modern image-guided radiotherapy reduces but does not eliminate these risks.

The best salvage window can occur before a scan turns positive

After prostatectomy, microscopic recurrence may produce a rising PSA long before PSMA PET can show a lesion. Outcomes are generally better when salvage radiotherapy is delivered at lower PSA levels, so imaging should inform the field and systemic-treatment discussion without causing avoidable delay.

Not every adverse pathology finding needs immediate radiation

Modern randomised evidence supports close PSA surveillance with early salvage radiotherapy for many men rather than routine adjuvant radiation for all adverse pathological features. This reduces overtreatment in men who may never recur. Selected very-high-risk situations still need individual discussion.

Hormonal therapy is added according to recurrence risk

The benefit of ADT with salvage radiation is greater in some higher-risk situations and must be balanced against hot flushes, sexual effects, metabolic changes and bone loss. PSA level, Grade Group, seminal-vesicle involvement, PSA doubling time and nodal risk all influence the decision.

Timing matters more than waiting for a very high PSA

After prostatectomy, a persistently detectable or rising PSA suggests residual or recurrent disease. Salvage radiotherapy generally works better when given at a low PSA rather than waiting for obvious metastatic disease, although the exact trigger depends on PSA trend, pathology, imaging and competing risks. PSMA PET can help define targets, but a negative scan at a low PSA does not rule out microscopic disease in the prostate bed or pelvic nodes.

When to seek earlier medical review

A rising or persistently detectable PSA after prostatectomy should be reviewed on the agreed timeline rather than deferred until symptoms appear. Urgent assessment is needed for new neurological weakness, loss of bladder/bowel control or severe uncontrolled bone pain.

What to bring to your consultation

• Prostatectomy HPE and operative report
• Serial postoperative PSA values
• PSMA PET/MRI if performed
• Previous hormone/radiation records

Questions to ask your doctor

• At what PSA would you recommend starting salvage radiation rather than continuing observation?
• Would a negative PSMA PET change that timing?
• Do my features justify adding ADT and for how long?

FAQs

Related reading

• Prostate Cancer: Symptoms, Diagnosis and Treatment
• PSA Test for Prostate Cancer
• Prostate MRI Explained
• Prostate Biopsy Report Explained
• Prostate Cancer Stages Explained
• Urologist in Latur

References

• European Association of Urology (EAU). Prostate Cancer Guidelines, 2026. Diagnostic Evaluation https://uroweb.org/guidelines/prostate-cancer/chapter/diagnostic-evaluation
• European Association of Urology (EAU). Prostate Cancer Guidelines, 2026. Treatment https://uroweb.org/guidelines/prostate-cancer/chapter/treatment
• National Cancer Institute. Prostate Cancer Treatment (PDQ) – Patient Version https://www.cancer.gov/types/prostate/patient/prostate-treatment-pdq